Malignant gliomas: New translational therapies

Mount Sinai Journal of Medicine

Volumn 77, Issue 6, 2010, Pages 655-666

  Sul, Joohee ^a   Fine, Howard A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

angiogenesis; epigenetics; glioblastoma; glioma stem cells; immunotherapy; malignant glioma; molecular profiles; signal transduction pathways; translational research; tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CEDIRANIB; DENDRITIC CELL VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GDC 0449; GEFITINIB; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PEPTIDE VACCINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; CANCER CLASSIFICATION; CANCER IMMUNIZATION; CANCER STEM CELL; CANCER SURVIVAL; CELL MOTILITY; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL TRIAL; DNA METHYLATION; DRUG DOSE ESCALATION; EPIGENETICS; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; MEDULLOBLASTOMA; OVERALL SURVIVAL; PHENOTYPE; PROGRESSION FREE SURVIVAL; PROMOTER REGION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EPIGENOMICS; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOTHERAPY; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; TRANSLATIONAL RESEARCH; VACCINES, SUBUNIT;

EID: 78649654663     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.20223     Document Type: Review

References (95)

1. CBTRUS (2010). CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. Hinsdale, IL: Central Brain Tumor Registry of the United States; February 2010.
2. Louis DN, Ohgaki H, Wiestler OD, et al., eds. WHO Classification of Tumours of the Central Nervous System. 3rd ed. Lyon, France: International Agency for Research on Cancer; 2007.
3. Stupp R, Mason WP, van den Bent MJ, et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
4. Stupp R, Hegi ME, Mason WP, et al., Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009; 10: 459-966.
5. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455: 1061-1068.
6. Verhaak RG, Hoadley KA, Purdom E, et al., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010; 17: 98-110.
7. Li A, Walling J, Ahn S, et al., Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 2009; 69: 2091-2099.
8. Madhavan S, Zenklusen JC, Kotliarov Y, et al., Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res 2009; 7: 157-167.
9. Belanich M, Pastor M, Randall T, et al., Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996; 56: 783-788.
10. Gerson SL., MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4: 296-307.
11. Jaeckle KA, Eyre HJ, Townsend JJ, et al., Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 1998; 16: 3310-3315.
12. Esteller M, Garcia-Foncillas J, Andion E, et al., Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents [published correction appears in N Engl J Med 2000;343:1740]. N Engl J Med 2000; 343: 1350-1354.
13. Hegi ME, Diserens AC, Gorlia T, et al., MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
14. Dolan ME, Mitchell RB, Mummert C, et al., Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 1991; 51: 3367-3372.
15. Wedge SR, Porteous JK, Newlands ES., 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 1996; 74: 1030-1036.
16. Quinn JA, Jiang SX, Reardon DA, et al., Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol 2009; 27: 1262-1267.
17. Quinn JA, Jiang SX, Carter J, et al., Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clin Cancer Res 2009; 15: 1064-1068.
18. Quinn JA, Pluda J, Dolan ME, et al., Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002; 20: 2277-2283.
19. Tolcher AW, Gerson SL, Denis L, et al., Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003; 88: 1004-1011.
20. Clarke JL, Iwamoto FM, Sul J, et al., Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma. J Clin Oncol 2009; 27: 3861-3867.
21. Libermann TA, Nusbaum HR, Razon N, et al., Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature 1985; 313: 144-147.
22. Yamazaki H, Fukui Y, Ueyama Y, et al., Amplification of the structurally and functionally altered epidermal growth factor receptor gene (c-erbB) in human brain tumors. Mol Cell Biol 1988; 8: 1816-1820.
23. Brown PD, Krishnan S, Sarkaria JN, et al., Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 2008; 26: 5603-5609.
24. Furnari FB, Fenton T, Bachoo RM, et al., Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007; 21: 2683-2710.
25. Sugawa N, Ekstrand AJ, James CD, et al., Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A 1990; 87: 8602-8606.
26. Rich JN, Reardon DA, Peery T, et al., Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 2004; 22: 133-142.
27. De Witt Hamer PC., Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro Oncol 2010; 12: 304-316.
28. Mellinghoff IK, Wang MY, Vivanco I, et al., Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 2005; 353: 2012-2024.
29. Cloughesy TF, Yoshimoto K, Nghiemphu P, et al., Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 2008; 5: e8.
30. Stommel JM, Kimmelman AC, Ying H, et al., Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318: 287-290.
31. Folkman J, Merler E, Abernathy C, et al., Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-288.
32. Gimbrone MA Jr, Leapman SB, Cotran RS, et al., Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136: 261-276.
33. Folkman J., Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
34. Keck PJ, Hauser SD, Krivi G, et al., Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 1989; 246: 1309-1312.
35. Jain RK, di Tomaso E, Duda DG, et al., Angiogenesis in brain tumours. Nat Rev Neurosci 2007; 8: 610-622.
36. Sun L, Hui AM, Su Q, et al., Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006; 9: 287-300.
37. Jain RK., Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-989.
38. Batchelor TT, Sorensen AG, di Tomaso E, et al., AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007; 11: 83-95.
39. Batchelor TT, Duda DG, di Tomaso E, et al., Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010; 28: 2817-2823.
40. Stark-Vance V., Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro Oncol 2005; 7: 369.
41. Friedman HS, Prados MD, Wen PY, et al., Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733-4740.
42. Kreisl TN, Kim L, Moore K, et al., Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740-745.
43. Vredenburgh JJ, Desjardins A, Herndon JE II, et al., Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007; 25: 4722-4729. (Pubitemid 350086473)
44. Guo P, Hu B, Gu W, et al., Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment. Am J Pathol 2003; 162: 1083-1093.
45. Leenders WP, Küsters B, Verrijp K, et al., Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option. Clin Cancer Res 2004; 10: 6222-6230.
46. Lamszus K, Kunkel P, Westphal M., Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 2003; 88: 169-177.
47. Kim KJ, Li B, Winer J, et al., Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362: 841-844.
48. Rubenstein JL, Kim J, Ozawa T, et al., Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2: 306-314.
49. Carson MJ, Reilly CR, Sutcliffe JG, et al., Mature microglia resemble immature antigen-presenting cells. Glia 1998; 22: 72-85.
50. Aloisi F., Immune function of microglia. Glia 2001; 36: 165-179.
51. Fathallah-Shaykh HM, Gao W, Cho M, et al., Priming in the brain, an immunologically privileged organ, elicits anti-tumor immunity. Int J Cancer 1998; 75: 266-276.
52. Ni HT, Spellman SR, Jean WC, et al., Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 2001; 51: 1-9.
53. Yu JS, Wheeler CJ, Zeltzer PM, et al., Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001; 61: 842-847.
54. Kikuchi T, Akasaki Y, Irie M, et al., Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001; 50: 337-344.
55. Liau LM, Prins RM, Kiertscher SM, et al., Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005; 11: 5515-5525.
56. Suter T, Biollaz G, Gatto D, et al., The brain as an immune privileged site: dendritic cells of the central nervous system inhibit T cell activation. Eur J Immunol 2003; 33: 2998-3006.
57. Rosenberg SA, Sherry RM, Morton KE, et al., Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol 2005; 175: 6169-6176.
58. Kikuchi T, Akasaki Y, Abe T, et al., Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004; 27: 452-459.
59. Walker DG, Laherty R, Tomlinson FH, et al., Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci 2008; 15: 114-121.
60. Ludewig B, Ochsenbein AF, Odermatt B, et al., Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000; 191: 795-804.
61. Sampson JH, Archer GE, Mitchell DA, et al., Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin Immunol 2008; 20: 267-275.
62. Heimberger AB, Crotty LE, Archer GE, et al., Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003; 9: 4247-4254.
63. Wu AH, Xiao J, Anker L, et al., Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J Neurooncol 2006; 76: 23-30.
64. Heimberger AB, Hussain SF, Aldape K., Tumor specific peptide vaccination in newly-diagnosed patients with GBM. J Clin Oncol 2006; 24: 2529.
65. Sampson JH, Archer GE, Bigner DD., Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patietns with GBM. J Clin Oncol 2008; 26: 2011.
66. Rosenberg SA, Yang JC, Restifo NP., Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-915.
67. Fine HA., Toward a glioblastoma vaccine: promise and potential pitfalls. J Clin Oncol 2004; 22: 4240-4243.
68. Wrzesinski SH, Wan YY, Flavell RA., Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin Cancer Res 2007; 13: 5262-5270.
69. O'Garra A, Barrat FJ, Castro AG, et al., Strategies for use of IL-10 or its antagonists in human disease. Immunol Rev 2008; 223: 114-131.
70. Bai A, Higham E, Eisen HN, et al., Rapid tolerization of virus-activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc Natl Acad Sci U S A 2008; 105: 13003-13008.
71. Uhl M, Aulwurm S, Wischhusen J, et al., SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo. Cancer Res 2004; 64: 7954-7961.
72. Bao S, Wu Q, McLendon RE, et al., Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444: 756-760.
73. Dietrich J, Imitola J, Kesari S., Mechanisms of disease: the role of stem cells in the biology and treatment of gliomas. Nat Clin Pract Oncol 2008; 5: 393-404.
74. Singh SK, Hawkins C, Clarke ID, et al., Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
75. Singh SK, Clarke ID, Terasaki M, et al., Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-5828.
76. Son MJ, Woolard K, Nam DH, et al., SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell 2009; 4: 440-452.
77. Phillips HS, Kharbanda S, Chen R, et al., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-173.
78. Purow BW, Haque RM, Noel MW, et al., Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005; 65: 2353-2363.
79. Kanamori M, Kawaguchi T, Nigro JM, et al., Contribution of Notch signaling activation to human glioblastoma multiforme. J Neurosurg 2007; 106: 417-427.
80. Fan X, Matsui W, Khaki L, et al., Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 2006; 66: 7445-7452.
81. Fan X, Mikolaenko I, Elhassan I, et al., Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res 2004; 64: 7787-7793.
82. Machold R, Hayashi S, Rutlin M, et al., Sonic hedgehog is required for progenitor cell maintenance in telencephalic stem cell niches. Neuron 2003; 39: 937-950.
83. Lai K, Kaspar BK, Gage FH, et al., Sonic hedgehog regulates adult neural progenitor proliferation in vitro and in vivo. Nat Neurosci 2003; 6: 21-27.
84. Cai C, Thorne J, Grabel L., Hedgehog serves as a mitogen and survival factor during embryonic stem cell neurogenesis. Stem Cells 2008; 26: 1097-1108.
85. Goodrich LV, Milenkovic L, Higgins KM, et al., Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277: 1109-1113.
86. Clement V, Sanchez P, de Tribolet N, et al., HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007; 17: 165-172.
87. Bar EE, Chaudhry A, Lin A, et al., Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma. Stem Cells 2007; 25: 2524-2533.
88. Macdonald DR, Cascino TL, Schold SC Jr, et al., Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277-1280.
89. Lieberman FS, Cloughesy T, Fine HA, et al., NABTC phase I/II trial of ZD-1839 for recurrent malignant gliomas and unresectable meningiomas. J Clin Oncol 2004; 22 (14S):Abstract 1510.
90. Uhm JH, Ballman KV, Giannini C, et al., Phase II study of ZD1839 in patients with newly diagnosed grade 4 astrocytoma. J Clin Oncol 2004; 22 (14S):Abstract 1505.
91. Franceschi E, Cavallo G, Lonardi S, et al., Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 2007; 96: 1047-1051.
92. Vogelbaum MA, Peereboom DM, Stevens G, et al., Phase II study of erlotinib single agent therapy in recurrent glioblastoma multiforme. Paper presented at: 29th ESMO Congress; October 29-November 3, 2004; Vienna, Austria.
93. Raizer JJ, Abrey LE, Wen P, et al., A phase II trial of erlotinib (OSI-774) in patients (pts) with recurrent malignant gliomas (MG) not on EIAEDs. J Clin Oncol 2004; 22 (14S):Abstract 1502.
94. Cloughesy T, Yung A, Vredenburgh J, et al., Phase II study of erlotinib in recurrent GBM: molecular predictors of outcome. J Clin Oncol 2005; 23 (16S, part 1):Abstract 1507.
95. Van den Bent MJ, Brandes AA, Rampling R, et al., Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol 2009; 27: 1268-1274.